HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.
Detailed genetic analysis refines ovarian cancer into more precise groups, helping doctors predict which patients benefit most from PARP inhibitor treatment.
WGS-based HRDetect algorithm stratifies advanced ovarian cancer into prognostically distinct groups beyond the conventional HRD/HRP binary, with HRDetect-high status predicting both superior overall survival and markedly improved PARP inhibitor response in an independent validation cohort. The newly described HRDetect-intermediate category (23.2% of patients) and 11 rearrangement signature clusters reveal greater genomic complexity than previously recognized, supporting refined precision oncology decision-making for PARPi selection.
What the study was
- Study design
- WGS-based cohort study with independent validation
- Population
- Advanced-stage tubo-ovarian carcinoma patients (UW cohort + ARIEL2 rucaparib trial)
- Sample size
- 262
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Clinical Cancer Research
Why it surfaced
HRDetect with rearrangement signature profiling substantially improves PARPi patient selection in OC: 54% vs 22.5% response rate and significant PFS benefit in independent validation. The intermediate category finding rewrites the HRD landscape. Nik-Zainal/Swisher authorship adds credibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.